The viability of synthetic lethality strategies has been demonstrated with the use of poly [ADP-ribose] polymerase (PARP) inhibitors, since tumor cells harboring BRCA1/2 mutations are 1000 times more sensitive to PARP inhibition than wild-type counterparts [82]. Here, BRCA1 is linked to neoplasm.